The Modified Mucosal Inflammation Noninvasive Index and Endoscopic Remission in Adults With Crohn's Disease

Article Gastroenterology & Hepatology

Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results

Geert R. D'Haens et al.

Summary: The SERENE CD trial demonstrated that higher adalimumab induction dosing was not superior to standard dosing, and clinically adjusted (CA) and therapeutic drug monitoring (TDM) maintenance strategies showed similar efficacy. Adalimumab therapy was well tolerated with no new safety concerns identified in this study.

GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD)

Neeraj Narula et al.

Summary: A modified multiplier of the Simple Endoscopic Score for Crohn's Disease (MM-SES-CD) was developed and validated to predict endoscopic remission in CD patients on active therapy. Baseline ulcer size, extent of ulceration, and presence of non-passable strictures were found to have the strongest association with achieving endoscopic remission. The MM-SES-CD demonstrated strong discrimination for endoscopic remission compared to the original SES-CD scoring model.

GUT (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Dan Turner et al.

Summary: STRIDE-II presents treatment targets for both adult and pediatric IBD, including long-term and short-term goals. These targets cover aspects such as clinical response, endoscopic healing, quality of life, and growth, providing guidance for improving patient outcomes.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Induction of Remission in Pediatric Crohn's Disease Patients Assessed by the Mucosal Inflammation Noninvasive Index

Roma Herman et al.

Summary: Mucosal healing is the main treatment goal of Crohn's disease, and the Mucosal Inflammation Noninvasive Index (MINI) shows promise in distinguishing mucosal healing from inflammation. This study evaluated MINI in monitoring remissions induced by exclusive enteral nutrition in pediatric CD patients, and found that MINI is superior to fecal calprotectin in predicting disease relapse.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Is Fecal Calprotectin a Useful Marker for Small Bowel Crohn Disease?

Giulia D'Arcangelo et al.

Summary: The study aimed to determine the diagnostic value of fecal calprotectin (FC) for colonic and ileocolonic Crohn's disease. Results showed that FC has lower sensitivity for isolated ileal CD (L1), and a lower threshold is needed to improve its performance.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2021)

添加到收藏夹

Article Gastroenterology & Hepatology